HKPD
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Trades at a low multiple of sales, but value is eroded by shrinking top-line growth.
- P/S below 1.0
- P/B is relatively low at 1.33
- No P/E available due to lack of profitability
- Graham Number cannot be calculated
Growth metrics are in a state of freefall, significantly underperforming the healthcare sector average of 101.13%.
- Revenue growth -35.70%
- Earnings growth -83.10%
- Q/Q earnings growth -81.40%
Consistent long-term and medium-term value destruction for shareholders.
- 5Y Change: -77.9%
- 1Y Change: -40.8%
- 6M Change: -47.7%
Balance sheet is the only area of stability, providing a buffer against immediate insolvency.
- Piotroski F-Score 4/9 (Stable)
- Low Debt/Equity
- High Current Ratio
- Negative ROE and ROA
- Negative profit margins
Non-dividend paying growth/speculative stock.
- No dividend yield
- 0% payout ratio
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for HKPD and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
HKPD
Cellyan Biotechnology Co., Ltd
Primary
|
-77.9% | -77.9% | -40.8% | -47.7% | -1.0% | +9.3% |
|
BMGL
Basel Medical Group Ltd
Peer
|
-82.0% | -82.0% | -82.0% | -64.4% | +23.8% | -3.5% |
|
CYCN
Cyclerion Therapeutics, Inc.
Peer
|
-93.9% | -46.5% | +40.9% | +36.5% | +133.6% | +124.5% |
|
HIND
Vyome Holdings, Inc.
Peer
|
-100.0% | -100.0% | -96.1% | -56.8% | -15.1% | +2.8% |
|
GNTA
Genenta Science S.p.A.
Peer
|
-93.8% | -88.7% | -82.4% | -79.4% | -21.2% | -4.4% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q3 2025
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
HKPD
Cellyan Biotechnology Co., Ltd
|
BEARISH | $14.62M | - | -13.4% | -4.3% | $0.62 | |
|
BMGL
Basel Medical Group Ltd
|
BEARISH | $15.03M | - | -194.6% | -99.8% | $0.8 | Compare |
|
CYCN
Cyclerion Therapeutics, Inc.
|
BEARISH | $15.07M | - | -39.3% | -170.1% | $3.48 | Compare |
|
HIND
Vyome Holdings, Inc.
|
BEARISH | $15.37M | - | -% | -% | $2.19 | Compare |
|
GNTA
Genenta Science S.p.A.
|
BEARISH | $16.02M | - | -38.0% | -% | $0.68 | Compare |
Past News Coverage
Recent headlines mentioning HKPD from our newsroom.